½ÃÀ庸°í¼­
»óǰÄÚµå
1378596

¼¼°è Ä¡·á¿ë ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°

Therapeutic Proteins And Oral Vaccines Market, By Drug Class (Therapeutic Proteins, Oral Vaccines ), By Application, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Ä¡·á ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀåÀº 2023³â 2¾ï 4,670¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£(2023-2030³â) µ¿¾È 8.1%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ´ë»ó ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁس⵵ 2022³â 2023³â ½ÃÀå ±Ô¸ð 2¾ï 4,670¸¸ ´Þ·¯
°ú°Å µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030³â
¿¹Ãø ±â°£ÀÇ CAGR 8.10% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 4¾ï 2,480¸¸ ´Þ·¯
±×¸² 1. Ä¡·á¿ë ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ¼¼°è ½ÃÀå Á¡À¯À²(%), ¾àÁ¦ Ŭ·¡½ºº°, 2023³â
Therapeutic Proteins And Oral Vaccines Market-IMG1

Ä¡·á ´Ü¹éÁúÀº ÀÓ»ó ¿ëµµ¿¡ µû¶ó »ý¹°ÇÐÀû Á¦ÇüÀÇ ÁÖ¿ä ¿É¼Ç Áß ÇϳªÀÔ´Ï´Ù. ´Ü¹éÁúÀº ºÐÀÚ·®ÀÌ Å« À¯±â È­ÇÕ¹°ÀÔ´Ï´Ù. À̰ÍÀº ¾Ï, ÈÄõ¼º ¸é¿ª°áÇÌ ÁõÈıº(AIDS), ´Ù¾çÇÑ °¨¿°Áõ µî ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ Ä¡·á È¿°ú°¡ ÀÖ½À´Ï´Ù. ´Ü¹éÁúÀÌ Ä¡·á ¸ñÀûÀ¸·Î »ç¿ëµÇ´Â °æ¿ì, ÀÌ´Â Ä¡·á ´Ü¹éÁú·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. Ä¡·á¿ë ´Ü¹éÁúÀº ´ç´¢º´À» Ä¡·áÇϱâ À§ÇÑ Àν¶¸°ÀÇ Á¦Á¶¿¡¼­ Á¦¾à ¸ñÀûÀ¸·Î ½ÇÇè½Ç¿¡¼­ Á¶À۵Ǵ ´Ü¹éÁúÀÔ´Ï´Ù. Ä¡·á ´Ü¹éÁúÀº »ýü ³»¿¡¼­ ¸Å¿ì È¿°úÀûÀ̸ç Áúº´ Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. °æ±¸ ¸é¿ªÀº ±âÁ¸ÀÇ ¹é½Åº¸´Ù ¼³ºñ°¡ °®Ãß¾îÁ® Àֱ⠶§¹®¿¡ ´Ù¸¥ ¾î¶² ¹é½Å Á¢Á¾ °æ·Îº¸´Ù °¡Àå Æí¸®ÇÑ ¹é½Å Á¢Á¾ °æ·Î·Î °£Áֵ˴ϴÙ. °æ±¸ ¹é½Å Á¢Á¾¿¡ ÀÇÇÑ Á¡¸· ¸é¿ªÀÇ È¹µæÀº Àΰ£¿¡¼­ Àΰ£À¸·Î, ¶Ç´Â µ¿¹°¿¡¼­ Àΰ£À¸·ÎÀÇ º´¿ø¼º °¨¿°¿¡ ´ëÇÑ º¸È£Àڷμ­ ±â´ÉÇϰí, ¹Ì»ý¹°ÀÌ ¼÷ÁÖÀÇ Ç÷¾× ¼øÈ¯¿¡ ħÀÔÇÏ´Â °¡Àå ¹Ù¶÷Á÷ÇÑ °æ·ÎÀÎ Á¡¸· ¿µ¿ª¿¡¼­ÀÇ º´¿ø¼º º¹Á¦¸¦ ¾ïÁ¦ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

Ä¡·á ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷´Â ¹é½Å°ú Á¦Ç° °³¹ß, ½ÃÀå ¼±¼öÀÇ ¿¬±¸ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­, ÀÌ·¯ÇÑ ¼±ÁøÀûÀÎ Á¦Ç° ½ÃÀå¿¡ ´ëÇÑ ¼Ò°³´Â ¿¹Ãø ±â°£¿¡ °ÉÃÄ ¼¼°èÀÇ Ä¡·á ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 9¿ù ÀÓ»ó ´Ü°èÀÇ »ý¸í °øÇРȸ»çÀÎ Vaxart, Inc.´Â ȸ»çÀÇ ¹«ÇÑ S Àü¿ë °æ±¸ Á¤Á¦ COVID-19 ¹é½Å Èĺ¸ÀÎ VXA-CoV2-1.1-SÀÇ °èȹµÈ 2ºÎ ´Ü°è II ½ÃÇèÀÇ Á¦1ºÎ·ÎºÎÅÍÀÇ ÁÁÀº Åé ¶óÀÎ µ¥ÀÌÅ͸¦ º¸°íÇß½À´Ï´Ù. ÀÌ µ¥ÀÌÅÍ´Â º» ¿¬±¸°¡ ÁÖ¿ä ¾ÈÀü¼º ¹× º¸Á¶ ¸é¿ª¿ø¼º Á¾Á¡À» ´Þ¼ºÇßÀ½À» º¸¿©ÁÖ¸ç, ¿À¹ÌÅ©·ÐÀ» ±â¹ÝÀ¸·Î ÇÏ´Â »õ·Î¿î ¹é½Å ±¸Á¶¹°ÀÇ Áö¼ÓÀûÀÎ °³¹ß¿¡ µµ¿òÀÌ µË´Ï´Ù.

º» ½ÃÇèÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­´Â ¼¼°è Ä¡·á¿ë ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2023-2030³â) ½ÃÀå ±Ô¸ð¸¦ Á¦°øÇÕ´Ï´Ù.
  • ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ¿£ÅÍÇÁ¶óÀÌÁî ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¾÷Àû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è Ä¡·á ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂûÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è Ä¡·á¿ë ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°è Ä¡·á ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç °áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

  • Á¶»çÀÇ ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
  • ¿µÇ⠺м®
  • ÃÖ±Ù Å×½ºÆ® ¹ß»ç
  • ¿ªÇÐ
  • ÇÕº´, Àμö ¹× Çù¾÷
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ÁÖ¿ä ¹ßÀü
  • PEST ºÐ¼®

Á¦4Àå ¼¼°è Ä¡·á¿ë ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀå : ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿µÇ⠺м®

  • °æÁ¦Àû ¿µÇâ
  • ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿ªÇÐ
  • ¼ö¿ä ¹× °ø±Þ¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦5Àå ¼¼°è Ä¡·á¿ë ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°(2018-2030³â)

  • Ä¡·á¿ë ´Ü¹éÁú
  • ¼ºÀåÀÎÀÚ
  • À¶ÇÕ ´Ü¹éÁú
  • ´ÜŬ·ÐÇ×ü
  • È£¸£¸ó
  • ÀÀ°í ÀÎÀÚ
  • ±âŸ
  • °æ±¸ ¹é½Å
  • ¾àµ¶»ý ¹é½Å
  • ºÒȰ¼ºÈ­ ¹é½Å
  • ÀçÁ¶ÇÕ ¹é½Å
  • ±âŸ

Á¦6Àå ¼¼°è Ä¡·á¿ë ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀå : ¿ëµµº°(2018-2030³â)

  • Á¾¾çÇÐ
  • Ç÷¾×ÇÐ
  • ¸é¿ªÇÐ
  • ³»ºÐºñÇÐ
  • °¨¿°Áõ
  • ¼øÈ¯±â Áúȯ
  • ±âŸ

Á¦7Àå ¼¼°è Ä¡·á¿ë ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀå : À¯Åë ä³Îº°(2018-2030³â)

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¼¼°è Ä¡·á¿ë ´Ü¹éÁú ¹× °æ±¸ ¹é½Å ½ÃÀå : Áö¿ªº°(2018-2030³â)

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿
  • GCC
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Abbott Laboratories
    • Amgen, Inc.
    • Biogen, Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson and Johnson
    • Merck &Co. Inc.
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • Sanofi SA
    • Serum Institute of India Pvt. Ltd.
    • Emergent Biosolutions Inc.
    • TransAlgae
    • MigVax Ltd.
    • Lumen Bioscience, Inc.

Á¦10Àå ¼½¼Ç

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
JHS 23.11.21

The Global Therapeutic Proteins And Oral Vaccines Market is estimated to be valued at US$ 246.7 Mn in 2023 and is expected to exhibit a CAGR of 8.1% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 246.7 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 8.10% 2030 Value Projection: US$ 424.8 Mn
Figure 1. Global Therapeutic Proteins and Oral Vaccines Market Share (%), By Drug Class, 2023
Therapeutic Proteins And Oral Vaccines Market - IMG1

Therapeutic proteins are one of the prime options for biologicals as per their clinical uses. Proteins are organic compounds with a higher molecular weight. This have therapeutic effects against various diseases like cancer, Acquired immunodeficiency syndrome (AIDS), and various infectious diseases. When protein is used for therapeutic purposes, it is known as a therapeutic protein. Therapeutic proteins are proteins that are engineered in the laboratory for pharmaceutical purposes in the making of insulin to treat diabetes. Therapeutic proteins are highly effective in vivo and have revolutionized the treatment of diseases. Oral immunization is considered the most convenient route of vaccination rather than any other route due to its abundance of facilities over the traditional vaccines. Gaining of mucosal immunity through oral vaccination can act as a protector against human-to-human or animal-to-human pathogenic transmission of diseases and also inhibit the pathogenic replication in the mucosal area which is the most preferable able route of microbe's penetration to the host blood circulation.

Market Dynamics

The key players in the therapeutic proteins and oral vaccines market are focusing on the development of vaccines, products, and research and development by market players. Thus, the introduction of such advanced products into the market is expected to drive growth of the global therapeutic proteins and oral vaccines market over the forecast period. For instance, in September 2022, Vaxart, Inc., a clinical-stage biotechnology company, reported positive top-line data from the first part of a planned two-part Phase II study of its Wuhan S-only oral pill COVID-19 vaccine candidate, VXA-CoV2-1.1-S. The data demonstrate that the trial met its primary safety and secondary immunogenicity endpoints and will inform the ongoing development of new Omicron-based vaccine constructs.

Key features of the study:

  • This report provides an in-depth analysis of the global therapeutic proteins and oral vaccines market and provides market size (US$ Mn and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global global therapeutic proteins and oral vaccines market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson and Johnson, Merck & Co.Inc., Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd., and Lumen Bioscience, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global therapeutic proteins and oral vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global therapeutic proteins and oral vaccines market

Therapeutic Proteins And Oral Vaccines Market Detailed Segmentation:

  • By Drug Class:
    • Therapeutic Proteins
    • Growth Factors
    • Fusion Proteins
    • Monoclonal Antibodies
    • Hormones
    • Coagulation Factors
    • Others
    • Oral Vaccines
    • Live Attenuated Vaccine
    • Inactivated Vaccine
    • Recombinant Vaccine
    • Others
  • By Application:
    • Oncology
    • Hematology
    • Immunology
    • Endocrinology
    • Infectious Disease
    • Cardiovascular Disease
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles
    • Abbott Laboratories
    • Amgen, Inc.
    • Biogen, Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson and Johnson
    • Merck & Co.Inc.
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • Sanofi S.A.
    • Serum Institute of India Pvt. Ltd.
    • Emergent Biosolutions Inc.
    • TransAlgae
    • MigVax Ltd.
    • Lumen Bioscience, Inc.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Test Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Therapeutic Proteins and Oral Vaccines Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Therapeutic Proteins and Oral Vaccines Market, By Drug Class, 2018- 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Therapeutic Proteins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
    • Segment Trends
  • Growth Factors
  • Fusion Proteins
  • Monoclonal Antibodies
  • Hormones
  • Coagulation Factors
  • Others
  • Oral Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
    • Segment Trends
  • Live Attenuated Vaccine
  • Inactivated Vaccine
  • Recombinant Vaccine
  • Others

6. Global Therapeutic Proteins and Oral Vaccines Market, By Application, 2018 - 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
    • Segment Trends
  • Hematology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
    • Segment Trends
  • Immunology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
    • Segment Trends
  • Endocrinology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
    • Segment Trends
  • Infectious Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
    • Segment Trends
  • Cardiovascular Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
    • Segment Trends

7. Global Therapeutic Proteins and Oral Vaccines Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

8. Global Therapeutic Proteins and Oral Vaccines Market, By Region, 2018 - 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Application, 2018 -2030, (US$ Mn)
    • Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
    • Market Size and Forecast, Y-o-Y Growth and By Country/Region, 2018 -2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • Abbott Laboratories
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Amgen, Inc.
    • Biogen, Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson and Johnson
    • Merck & Co. Inc.
    • Novo Nordisk A/S
    • Pfizer, Inc.
    • Sanofi S.A.
    • Serum Institute of India Pvt. Ltd.
    • Emergent Biosolutions Inc.
    • TransAlgae
    • MigVax Ltd.
    • Lumen Bioscience, Inc.

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦